Floatz logo

Zuberitamab

Marginal Zone Lymphoma(MZL)

Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

105 Active assets in the Marginal Zone Lymphoma(MZL) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Zuberitamab is also rated in:

mantle cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
Bispecific AntibodyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →